This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Doxepin

Selective H1 antagonist at 3-6 mg.

Aliases (5)

Silenor · Sinequan · low-dose doxepin · 3 mg doxepin · 6 mg doxepin

TYPICAL DOSE

—

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Doxepin?

Selective H1 antagonist at 3-6 mg. One of the safest pharmacological options for sleep-maintenance insomnia. No dependence, no REM suppression, no parasomnia risk. OPTIONAL-ADD if sleep maintenance ever a problem.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Was this helpful?

Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸

Loading…

Continue: Extended research →

Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Doxepin

STRONG-CANDIDATE

Pineal hormone — endogenous indoleamine; MT1/MT2 melatonin receptor agonist; circadian phase-shift signal

Dual Orexin Receptor Antagonist (DORA) — sleep medication; first-in-class

Dual Orexin Receptor Antagonist (DORA) — sleep medication

Tetracyclic antidepressant — Noradrenergic and Specific Serotonergic Antidepressant (NaSSA) — Organon (now Merck/Schering-Plough/Organon&Co)